688013.SHG Touchstone International Medical Science Co Ltd
- Market cap
- CNY 1.73B
- P/E
- 59.3x
- P/B
- 3.30x
- ROE
- 5.6%
- Dividend yield
- 7.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688013.SHG undervalued?
Graham number688013.SHG trades 195.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Touchstone International Medical Science Co Ltd fundamental analysis
No fundamental analysis for Touchstone International Medical Science Co Ltd yet.
Touchstone International Medical Science Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Touchstone International Medical Science Co Ltd
Touchstone International Medical Science Co., Ltd. researches and develops, manufactures, and sells medical devices in China, the United States, Europe, Japan, Russia, Brazil, South Korea, Canada, Australia, and internationally. It provides laparoscopic, tube-type, intraluminal, endoscopic linear cutters and reloads, linear cutters and reloads, auto purse string clamps, and linear staplers and reloads, as well as proctological, circumcision, and circular staplers. It offers …
Full company profileTouchstone International Medical Science Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Touchstone International Medical Science Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 89.6M | 119M | 173M | 163M | 214M | 232M | 254M | 272M | 327M | 227M |
| Gross Profit | 54.5M | 69.8M | 104M | 95.1M | 122M | 132M | 142M | 159M | 327M | 141M |
| Operating Income | 13.7M | 23.8M | 45.1M | 34.4M | 44.9M | 44.1M | 46.4M | 55.0M | 94.2M | 16.5M |
| EBITDA | 18.2M | 31.3M | 54.5M | 46.8M | 53.4M | 54.3M | 57.2M | 64.4M | 103M | 31.7M |
| Net Income | 13.9M | 23.1M | 42.0M | 34.9M | 41.4M | 43.2M | 47.3M | 51.9M | 84.1M | 27.5M |
| EPS | 0.23 | 0.39 | 0.70 | 0.54 | 0.51 | 0.53 | 0.58 | 0.64 | 1.05 | 0.34 |
| Balance Sheet | ||||||||||
| Total Assets | 98.6M | 117M | 125M | 485M | 545M | 543M | 627M | 637M | 673M | 664M |
| Total Liabilities | 18.7M | 34.1M | 17.7M | 19.4M | 32.7M | 35.0M | 55.1M | 55.8M | 107M | 170M |
| Shareholders' Equity | 79.8M | 82.9M | 107M | 466M | 512M | 508M | 572M | 581M | 566M | 495M |
| Cash & Short-term Investments | 22.9M | 18.5M | 18.8M | 379M | 431M | 362M | 430M | 395M | 123M | 56.7M |
| Total Debt | - | 9.00M | - | - | - | 962K | 1.96M | 1.08M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 7.88M | 34.4M | 34.8M | 42.1M | 61.0M | 50.4M | 82.9M | 53.4M | 72.0M | - |
| Capital Expenditure | 15.2M | 20.8M | 9.41M | 7.29M | 9.21M | 47.7M | 18.4M | 41.9M | 90.7M | 55.9M |
| Free Cash Flow | -7.32M | 13.7M | 25.4M | 34.8M | 51.8M | 2.73M | 64.5M | 11.5M | -18.8M | -42.2M |
| Ratios | ||||||||||
| ROE | 17.4% | 27.9% | 39.2% | 7.5% | 8.1% | 8.5% | 8.3% | 8.9% | 14.9% | 5.6% |
| ROA | 14.1% | 19.8% | 33.6% | 7.2% | 7.6% | 7.9% | 7.6% | 8.1% | 12.5% | 4.1% |
| Net Profit Margin | 15.5% | 19.4% | 24.3% | 21.4% | 19.4% | 18.6% | 18.7% | 19.1% | 25.7% | 12.1% |
| Debt to Equity | - | 0.11x | - | - | - | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Touchstone International Medical Science Co Ltd dividends
- Dividend yield
- 7.01%
- Forward dividend
- 0.80 CNY
- Payout ratio
- 144.6%
- Ex-dividend date
- Jun 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 122M | 1.52 | 144.6% |
| 2024 | CNY 38.3M | 0.47 | 73.8% |
| 2023 | CNY 19.8M | 0.24 | 41.9% |
| 2022 | CNY 15.8M | 0.19 | 36.6% |
| 2021 | CNY 16.0M | 0.20 | 38.6% |
| 2020 | CNY 16.0M | 0.25 | 45.8% |
| 2019 | CNY 18.0M | 0.30 | 42.9% |
| 2018 | 18.0M | 0.30 | 77.9% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Touchstone International Medical Science Co Ltd
- Insiders 56.83%
- Institutions 3.21%
- Public & others 39.96%
- Shares outstanding 81.2M
- Free float 34.8M
Touchstone International Medical Science Co Ltd company profile
- Company name
- Touchstone International Medical Science Co Ltd
- Ticker
- 688013.SHG
- ISIN
- CNE1000042J3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 289
- Fiscal year end
- December
- Address
- No. 278, Dongping Street, Suzhou, China, 215123
- Phone
- 86 51 2629 91900
- Website
- touchstone.hk
About Touchstone International Medical Science Co Ltd
Touchstone International Medical Science Co., Ltd. researches and develops, manufactures, and sells medical devices in China, the United States, Europe, Japan, Russia, Brazil, South Korea, Canada, Australia, and internationally. It provides laparoscopic, tube-type, intraluminal, endoscopic linear cutters and reloads, linear cutters and reloads, auto purse string clamps, and linear staplers and reloads, as well as proctological, circumcision, and circular staplers. It offers its products for use in laparoscopic and open surgeries. The company was founded in 2003 and is based in Suzhou, the People's Republic of China.
Touchstone International Medical Science Co Ltd management
4- Mr. Wangyu ChenChairman & CEO · born 1966
- Ms. Guoyu TianCFO, Board Secretary, Accounting Supervisor & Director · born 1979
- Mr. Bin HuangVice President of Strategic R&D · born 1981
- Mr. Shui Cheng DingR&D Technical Director · born 1968